NUBEQA (darolutamide) 300 mg tablets logo NUBEQA (darolutamide) 300 mg tablets logo
Sign up for updates
NUBEQA (darolutamide) 300 mg tablets logo NUBEQA (darolutamide) 300 mg tablets logo
Sign up for updates

UNDERSTANDING PROSTATE CANCER

Black man in blue shirt holding and looking at a tablet device

Learning about prostate cancer and the different forms of the disease may help you better understand your diagnosis and feel more confident in making treatment decisions with your care team.

Below is a brief overview of the disease that you may find useful. A glossary of key terms is included at the bottom of the page.

What is prostate cancer?

Prostate cancer takes place in the prostate, a small gland located below the bladder, and happens when the body cannot control the growth of abnormal prostate cells.

Prostate cancer may become metastatic, which means it has spread to other parts of the body, such as the bones, lungs, liver, or distant lymph nodes.

Prostate cancer highlighted

Non-metastatic: cancer has not spread beyond the prostate

Graphic of cancer spreading outside the prostate

Metastatic: cancer has
spread beyond the prostate

Non-metastatic:
cancer has not spread
beyond the prostate

Prostate cancer highlighted
Graphic of cancer spreading outside the prostate

Metastatic:
cancer has spread
beyond the prostate

    WHAT ARE THE POSSIBLE SYMPTOMS OF PROSTATE CANCER?

    Prostate cancer symptoms can vary from person to person, with many men experiencing no symptoms at all.

    Talk to your doctor right away if you experience any of these symptoms:

    • Frequent urination, especially at night
    • A weak or interrupted flow of urine
    • Bloody urine or semen
    • Pain or burning during urination
    • Difficulty achieving an erection
    • Painful ejaculation
    • Pain in the back, hips, or pelvis that doesn’t go away

     

    The symptoms above can be caused by conditions other than prostate cancer.

    NUBEQA is not approved to treat these symptoms.

      HOW IS PROSTATE CANCER FOUND?

      Prostate cancer can be detected by healthcare providers in different ways, including:

      • Digital rectal exams (DREs)
      • Prostate-specific antigen (PSA) blood tests
      • Magnetic resonance imaging (MRI) scans
      • Prostate biopsies
      • Computed tomography (CT) scans

       

      Prostate cancer is usually found when it is still in the prostate, but in some cases the cancer is found after it has spread to other parts of the body.

        WHAT ARE THE RISK FACTORS FOR PROSTATE CANCER?

        The primary risk factor for prostate cancer is age—the older a man is, the greater his risk.

        Graphic of prostate cancer risk increasing with age

        Other risk factors include:

        Icon of man indicating ethnicity

        Ethnicity

        Increased risk in Black men, which may be due to access to screening and treatment, genetics, and other factors

        Icon of microscope and genes

        Family history and genetic factors

        Having genes, lifestyle habits, or environmental conditions that are similar to close relatives who have prostate cancer

        Icon of plus size body with up arrow

        Lifestyle and diet

        Tobacco and alcohol consumption, obesity, and not being physically active

          WHAT ARE THE TYPES OF PROSTATE CANCER?

          Prostate cancer can be categorized by whether or not it has spread beyond the prostate, as well as 
          by how it responds to hormone therapy.*

          Types of prostate cancer include:

          Graphical image of types of prostate cancer

          *Hormone therapy includes drug treatments or surgery to lower testosterone.

          You have support from all sides

          Being diagnosed with prostate cancer can be hard to grapple with. Don’t go through it alone. You have access to a strong support network of friends and family, medical professionals, advocacy organizations, and fellow patients who can raise you up when you’re at your lowest.

            Glossary

            Castration-resistant prostate cancer (CRPC): prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (ie, no longer responds to hormone therapy)

            Computed tomography (CT) scan: a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body

            Digital rectal exam (DRE): when a doctor inserts a lubricated, gloved finger into the rectum to feel for abnormalities

            Hormone-sensitive prostate cancer (HSPC): prostate cancer that can be treated with hormone therapy. Also called castration-sensitive prostate cancer (CSPC)

            Hormone therapy: drug treatments or surgery to lower testosterone to delay the growth of prostate cancer. Also called androgen deprivation therapy, or ADT

            Localized prostate cancer: cancer that has not spread beyond the prostate. Also called non-metastatic prostate cancer

            Magnetic resonance imaging (MRI): a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body

            Metastatic castration-resistant prostate cancer (mCRPC): prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy

            Metastatic hormone-sensitive prostate cancer (mHSPC): prostate cancer that has spread to other parts of the body and can be treated with hormone therapy

            Non-metastatic castration-resistant prostate cancer (nmCRPC): prostate cancer that has not spread to other parts of the body and no longer responds to hormone therapy

            Prostate biopsy: a procedure to remove tissue samples from the prostate

            Prostate-specific antigen (PSA) test: a test that measures the amount of PSA found in the blood. PSA is a protein made by the prostate gland. PSA levels may be higher in men with prostate cancer or other prostate-related conditions

            NUBEQA is approved to treat 2 types of prostate cancer

            Select the type of cancer you want to learn about:

            Learn about mHSPC† Learn about nmCRPC

            †NUBEQA is approved in combination with docetaxel (chemotherapy) for mHSPC.

            About NUBEQA

            Important Safety Information

            Before taking NUBEQA, tell your healthcare provider about all your medical conditions, including if you:

            • have heart problems, high blood pressure, diabetes, or high amounts of fat or cholesterol in your blood (dyslipidemia)
            • have a history of seizures, brain injury, stroke, or brain tumors
            • have kidney or liver problems
            • are pregnant or plan to become pregnant. NUBEQA can cause harm to your unborn baby and loss of pregnancy (miscarriage)
            • have a partner who may become pregnant. Males who have female partners who may become pregnant should use effective birth control (contraception) during treatment and for 1 week after the last dose of NUBEQA. Talk with your healthcare provider about birth control methods
            • are breastfeeding or plan to breastfeed. It is not known if NUBEQA passes into breast milk

            Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NUBEQA may affect the way other medicines work and other medicines may affect how NUBEQA works.

            You should not start or stop any medicine before you talk with the healthcare provider that prescribed NUBEQA.

            Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist when you get a new medicine.

            NUBEQA may cause serious side effects, including:

            • Heart disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with NUBEQA. Your healthcare provider will monitor you for signs and symptoms of heart problems during your treatment with NUBEQA. Call your healthcare provider or get medical help right away if you get chest pain or discomfort at rest or with activity, or shortness of breath during your treatment with NUBEQA
            • Seizure. Treatment with NUBEQA may increase your risk of having a seizure. You should avoid activities where a sudden loss of consciousness could cause serious harm to yourself or others. Tell your healthcare provider right away if you have loss of consciousness or seizure

            The most common side effects of NUBEQA in people with nmCRPC include:

            • increase in liver function tests
            • decreased white blood cells (neutropenia)
            • feeling more tired than usual
            • arm, leg, hand, or foot pain
            • rash

            The most common side effects of NUBEQA when used in combination with docetaxel in people with mHSPC include:

            • constipation
            • rash
            • decreased appetite
            • bleeding
            • weight gain
            • high blood pressure
            • decreased red blood cells (anemia)
            • high blood sugar levels
            • decreased white blood cells
            • increase in liver function tests
            • low blood calcium levels

            NUBEQA may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

            These are not all the possible side effects of NUBEQA.

            Call your healthcare provider for medical advice about side effects. You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

            Please see the full Prescribing Information.

            WHAT IS NUBEQA<sup>&reg;</sup>?

            NUBEQA® (darolutamide) is a prescription medicine used to treat adults with prostate cancer:

            • that has not spread to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone (non-metastatic castration-resistant prostate cancer or nmCRPC),
            • or
            • that has spread to other parts of the body and responds to medical or surgical treatment that lowers testosterone (metastatic hormone-sensitive prostate cancer or mHSPC), in combination with docetaxel

            It is not known if NUBEQA is safe and effective in women or children.

            © 2024 Bayer. All rights reserved. BAYER, the Bayer Cross and NUBEQA are registered trademarks of Bayer, and Access Services by Bayer is a trademark of Bayer.

            Date of last update: 09/12/2024